Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; AÃ, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
IPO Year:
Exchange: NASDAQ
Website: prothena.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/30/2024 | $68.00 → $38.00 | Buy → Neutral | BofA Securities |
| 12/12/2023 | $62.00 | Buy | Deutsche Bank |
| 4/24/2023 | $80.00 | Outperform | SVB Securities |
| 1/27/2023 | $94.00 | Overweight | Piper Sandler |
| 11/4/2022 | $52.00 → $55.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 9/28/2022 | Neutral → Buy | BofA Securities | |
| 11/19/2021 | $77.00 | Market Outperform | JMP Securities |
| 9/30/2021 | $59.00 → $82.00 | Outperform | RBC Capital |
| 9/27/2021 | $90.00 → $100.00 | Outperform | Oppenheimer |
| 9/20/2021 | $14.00 | Overweight | Fox Advisors |
Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash position was $520.1 million PRX012, a potential single-injection once-monthly subcutaneous treatment, is designed to address the unmet need of millions of patients with presymptomatic or early symptomatic Alzheimer's disease; Prothena expects to report multiple clinical readouts starting in mid-2025 and continuing throughout the year from the ongoing Phase 1 ASCENT clinical trials Results from partner Roche evaluating prasinezumab in patients with early Parkinson's disease from the Phase 2 PASA
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third quarter and first nine months of 2024 financial results on Tuesday, November 12, 2024, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on November 12. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the p
Chad J. Swanson, Ph.D., appointed Chief Development Officer and will lead clinical development and medical functions Hideki Garren, MD, Ph.D., Chief Medical Officer, will pursue an opportunity at a large pharmaceutical company to lead a global product development division Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Chad Swanson, Ph.D., has been appointed Chief Development Officer and will assume leadership of clinical development and medical functions. Chad will join Prothena's executive leadership team and will report to Gene Kin
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5; 1x1 investor meetings will be held Cantor Global Healthcare Conference on Tuesday, September 17; a fireside chat will be held at 1:55 PM ET A live webcast of the fireside chat can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live present
Net cash provided by operating and investing activities was $15.8 million in the second quarter and net cash used by operating and investing activities was $57.3 million for the first six months of 2024; quarter-end cash and restricted cash position was $565.0 million Revised year-end cash guidance to be approximately $468 million in cash, cash equivalents and restricted cash, representing an increase of $63 million from prior guidance of $405 million Bristol Myers Squibb obtained the exclusive global license for PRX019 for $80 million, a potential treatment of neurodegenerative disease with an undisclosed target; Prothena to initiate a Phase 1 clinical trial by YE 2024 Partner Br
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2024 financial results on Thursday, August 8, 2024, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on August 8. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the pot
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate a Phase 1 clinical trial for PRX019 in 2024 Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Bristol Myers Squibb obtained the exclusive global license for PRX019 and will pay Prothena $80 million. The U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for PRX019, a potential treatment of neu
Net cash used in operating and investing activities was $73.2 million in the first quarter of 2024; quarter-end cash and restricted cash position was $548.7 million Advanced potential best-in-class Alzheimer's disease portfolio: initial data supportive of ongoing Phase 1 clinical trial for PRX012, an anti-amyloid beta antibody; received FDA clearance for IND application and Fast Track designation for PRX123, a dual amyloid beta/tau vaccine; Phase 2 clinical trial initiated in patients with early Alzheimer's disease for BMS-986446 (formerly PRX005) by partner Bristol Myers Squibb Strengthened leadership position in the amyloidosis community with ongoing enrollment of the confirmatory
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on May 8. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced the publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab, a potential best-in-class anti-amyloid treatment for AL amyloidosis. The publication can be found in the latest issue of Leukemia & Lymphoma, an international peer-reviewed journal that publishes research on all aspects of hematological malignancies. AL amyloidosis is an idiopathic, rare, progressive and often fatal disease characterized by amyloid deposits that build up in vi
BofA Securities downgraded Prothena from Buy to Neutral and set a new price target of $38.00 from $68.00 previously
Deutsche Bank initiated coverage of Prothena with a rating of Buy and set a new price target of $62.00
SVB Securities initiated coverage of Prothena with a rating of Outperform and set a new price target of $80.00
Piper Sandler initiated coverage of Prothena with a rating of Overweight and set a new price target of $94.00
RBC Capital Mkts downgraded Prothena from Outperform to Sector Perform and set a new price target of $55.00 from $52.00 previously
BofA Securities upgraded Prothena from Neutral to Buy
JMP Securities initiated coverage of Prothena Corp with a rating of Market Outperform and set a new price target of $77.00
RBC Capital reiterated coverage of Prothena Corp with a rating of Outperform and set a new price target of $82.00 from $59.00 previously
Oppenheimer reiterated coverage of Prothena Corp with a rating of Outperform and set a new price target of $100.00 from $90.00 previously
Fox Advisors initiated coverage of Prothena Corp with a rating of Overweight and set a new price target of $14.00
SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
SC 13G - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
SC 13G - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
SC 13G - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
RBC Capital analyst Brian Abrahams reiterates Prothena Corp (NASDAQ:PRTA) with a Sector Perform and maintains $28 price target.
JMP Securities analyst Jason Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and lowers the price target from $85 to $83.
HC Wainwright & Co. analyst Andrew Fein maintains Prothena Corp (NASDAQ:PRTA) with a Buy and lowers the price target from $90 to $84.
Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(1.34) per share which missed the analyst consensus estimate of $(1.20) by 11.67 percent. The company reported quarterly sales of $900.00 thousand which missed the analyst consensus estimate of $2.17 million by 58.44 percent. This is a 58.51 percent decrease over sales of $2.17 million the same period last year.
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced the publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab, a potential best-in-class anti-amyloid treatment for AL amyloidosis. The publication can be found in the latest issue of Leukemia & Lymphoma, an international peer-reviewed journal that publishes research on all aspects of hematological malignancies.AL amyloidosis is an idiopathic, rare, progressive and often fatal disease characterized by amyloid deposits that build up in vital
Cantor Fitzgerald analyst Charles Duncan reiterates Prothena Corp (NASDAQ:PRTA) with a Overweight.
Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Prothena Corp (NASDAQ:PRTA) in the last three months. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 4 3 0 0 Last 30D 1 0 0 0 0 1M Ago 0 2 1 0 0 2M Ago 0 0 2 0 0 3M Ago 0 2 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $72.5, a high estimate of $129.00, and a low estimate of $35.00. Observing a downward trend, the current average is 6.88
HC Wainwright & Co. analyst Andrew Fein maintains Prothena Corp (NASDAQ:PRTA) with a Buy and maintains $90 price target.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume NVAX PUT SWEEP BEARISH 01/16/26 $2.50 $80.7K 7.9K 4.8K CVS PUT SWEEP BULLISH 03/08/24 $75.00 $36.8K 2
4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
3 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
10-Q - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
S-8 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
10-Q - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
10-Q - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
ARS - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash position was $520.1 million PRX012, a potential single-injection once-monthly subcutaneous treatment, is designed to address the unmet need of millions of patients with presymptomatic or early symptomatic Alzheimer's disease; Prothena expects to report multiple clinical readouts starting in mid-2025 and continuing throughout the year from the ongoing Phase 1 ASCENT clinical trials Results from partner Roche evaluating prasinezumab in patients with early Parkinson's disease from the Phase 2 PASA
Net cash used in operating and investing activities was $73.2 million in the first quarter of 2024; quarter-end cash and restricted cash position was $548.7 million Advanced potential best-in-class Alzheimer's disease portfolio: initial data supportive of ongoing Phase 1 clinical trial for PRX012, an anti-amyloid beta antibody; received FDA clearance for IND application and Fast Track designation for PRX123, a dual amyloid beta/tau vaccine; Phase 2 clinical trial initiated in patients with early Alzheimer's disease for BMS-986446 (formerly PRX005) by partner Bristol Myers Squibb Strengthened leadership position in the amyloidosis community with ongoing enrollment of the confirmatory
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it has named David Ford to a newly created position of Chief People Officer, reporting to Prothena President and Chief Executive Officer Gene Kinney, PhD. In this role, Mr. Ford will be responsible for people, culture, and human resources strategy to drive the company's vision and overall growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240304692974/en/David Ford, Chief People Officer, Prothena (Photo: Business Wire
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Daniel G. Welch to its Board of Directors as an independent director and Chair Designate following a comprehensive search process in connection with the board's regular succession planning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240221419945/en/Daniel G. Welch (Photo: Business Wire) Upon election by the shareholders at Prothena's Annual General Meeting later this year, the Board intends to appoint Mr. Welch a
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Billy Dunn, M.D., to its Board of Directors. Dr. Dunn is the founding and former Director of the Office of Neuroscience, Center for Drug Evaluation and Research (CDER), at the U.S. Food and Drug Administration (FDA). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005750/en/Dr. Billy Dunn joins the Prothena Board of Directors (Photo: Business Wire) "For nearly two decades, Dr. Dunn has dedicated his career as a
DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Helen S. Kim, MBA, to its Board of Directors. Ms. Kim has over 27 years of experience in leadership roles in biotechnology, including her previous role as Executive Vice President of Business Development at Kite Pharma, Inc. where she led all business and corporate development initiatives, leading to a successful acquisition by Gilead in 2017. With the appointment of Ms. Kim, Prothena will expand its Board to 10 directors. "M
DUBLIN, Ireland, May 20, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Sanjiv K. Patel, MBBS, MA, MBA, to its Board of Directors. "Sanjiv is an experienced leader with significant industry experience that uniquely positions him to guide us as we look towards transitioning to a fully integrated research, development and commercial biotechnology company," commented Lars Ekman, MD, PhD, Prothena's Chairman. "We welcome Sanjiv to our Board and look forward to his contributions in advising Prothena during this trans
DUBLIN, Ireland, April 05, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced the appointment of Hideki Garren, MD, PhD, as Chief Medical Officer. Dr. Garren will lead the clinical and medical organizations to advance Prothena’s clinical pipeline. “Hideki brings valuable experience and expertise to our team as we look ahead towards transitioning to a fully integrated research, development and commercial biotechnology company,” said Gene Kinney, PhD, President and Chief Executive Offic
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third quarter and first nine months of 2024 financial results on Tuesday, November 12, 2024, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on November 12. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the p
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2024 financial results on Thursday, August 8, 2024, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on August 8. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the pot
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on May 8. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of
Net cash used in operating and investing activities was $52.6 million in the fourth quarter and $136.7 million for the full year of 2023; quarter-end cash and restricted cash position was $621.0 million The company expects cash guidance for the full year 2024 net cash used in operating and investing activities to be $208 to $225 million and expects to end the year with approximately $405 million in cash (midpoint) Advanced potential best-in-class Alzheimer's disease portfolio in 2023: initial data supportive of ongoing Phase 1 clinical trial for PRX012, an anti-amyloid beta antibody; received FDA clearance for IND application and Fast Track designation for PRX123, a dual amyloid beta
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024 after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET. The conference call will be made available on the Company's website at www.prothena.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days. To
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third quarter and first nine months of 2023 financial results on Thursday, November 2, 2023 after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on November 2. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2023 financial results on Thursday, August 3, 2023 after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on August 3. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the pote
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2023 financial results on Thursday, May 4, 2023 after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on May 4. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of d
Net cash used in operating and investing activities was $5.1 million in the fourth quarter and $109.3 million for the full year of 2022; quarter-end cash and restricted cash position was $712.6 million Advanced potential best-in-class Alzheimer's Disease portfolio in 2022: received FDA clearance for IND application and Fast Track designation granted for PRX012, an investigational anti-Aβ antibody therapy; initiated Phase 1 SAD and MAD study for PRX012; completed Phase 1 SAD and initiated MAD study for PRX005, an investigational tri-epitopic antibody that specifically binds within the MTBR-tau Strengthened leadership position in the amyloidosis community with the ongoing enrollment of
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2022 financial results on Thursday, February 23, 2023 after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET. The conference call will be made available on the Company's website at www.prothena.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days. To a